Introduction
Charles B. Nemeroff, MD, PhD
Chair
Reunette W. Harris Professor and Chairman
Department of Psychiatry and Behavioral Sciences
Emory University School of Medicine
Atlanta
Clinical Grants: Abbott, American Foundation for Suicide Prevention (AFSP), AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, Inc., GlaxoSmithKline, Janssen, Merck & Co, Inc., National Alliance for Research On Schizophrenia and Depression (NARSAD), National Institute of Mental Health (NIMH), Pfizer, The Stanley Foundation/National Alliance for the Mentally Ill (NAMI), and Wyeth.
Consultant: Abbott, ACADIA Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Corcept Therapeutics Inc., Cypress, Cyberonics, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Janssen, Neurocrine Biosciences, Inc., Organon, Otsuka America Pharmaceutical, Inc., Quintiles Transnational Corp., Sanofi-Synthelabo, Inc., Somerset Pharmaceuticals, Inc., and Wyeth.
Speaker's Bureau: Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Janssen, Organon, Otsuka, Pfizer and Wyeth.
Board of Directors: AFSP, American Psychiatric Institute for Research and Education (APIRE), The George West Mental Health Foundation and NovaDel Pharma, Inc.
Stockholder: Corcept and Neurocrine Biosciences.
Holds a US patent on the Method and devices for transdermal delivery of lithium and has a provisional patent filing on the Method to estimate serotonin and norepinephrine transporter occupancy after drug treatment using patient or animal serum.

Genetics, Neuroanatomy, and Neurobiology
Daniel R. Weinberger, MD
Chief, Clinical Brain Disorders Branch
National Institute of Mental Health
Bethesda, MD
Advisory Board: Pfizer

Long-Term Management: A Phase Approach
Jeffrey A. Lieberman, MD
Thad and Alice Eure Distinguished Professor of Psychiatry
Vice Chairman, Department of Psychiatry
University of North Carolina School of Medicine
Chapel Hill
Clinical Grants: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline, Jansssen Pharmaceutica Products, LP, Novartis Pharmaceuticals Corporation, Organon Inc., and Pfizer Inc.
Consultant: Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, and Solvay Pharmaceuticals.
Advisory Board: Abbott, AstraZeneca, Aventis Pharmaceuticals, Inc., Bristol-Myers Squibb, Eli Lilly, GlaxoSmith Kline, Organon, Pfizer, and Solvay.
Shareholder: Cyberonics, Inc. and Cypress Bioscience, Inc.

Atypical Antipsychotics: Weighing the Benefits
Charles B. Nemeroff, MD

Cognition and Schizophrenia
Carol A. Tamminga, MD
Professor
Department of Psychiatry
University of Texas Southwestern Medical Center at Dallas
Clinical Grants: AstraZeneca and the NIMH.
Consultant: Avera Pharmaceuticals, Inc., Carlsson Research AB, and Neurogen Corporation.
Ad Hoc Consultant: Abbott, AstraZeneca, Janssen, Eli Lilly, Pfizer and Solvay.

This activity has been developed for psychiatrists and other mental health care professionals who are involved in the diagnosis and treatment of patients with schizophrenia.

Recent advances have been made in several significant areas concerning schizophrenia. These include the discovery of specific genes that confer an increased risk of schizophrenia and new understanding about cognitive functioning in patients with this disorder. As a result of these developments, new pharmacologic strategies are being investigated, and new paradigms for earlier identification of patients are being explored. This supplement provides clinicians with an overview of the latest developments in these areas.

By reading and studying this supplement, participants should be able to discuss:

• The recent findings of genes that confer a risk for schizophrenia and how these may affect neuroanatomy, neurobiology, and neurochemistry.

• The risks and benefits of conventional and atypical antipsychotic medications.

• New hypotheses concerning cognition as an independent factor in patients with schizophrenia.

• An approach to treatment of schizophrenia based on the phases of the disease.

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Excerpta Medica, Inc., and Clinical Psychiatry News. Excerpta Medica is accredited by the ACCME to provide continuing medical education for physicians.

Excerpta Medica designates this educational activity for a maximum of 1.25 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the educational activity.

The American Medical Association has determined that non-U.S. licensed physicians who participate in this activity are eligible for AMA/Physician's Recognition Award category 1 credit.

Term of approval: July 2004–June 30, 2005.

Copyright © 2004 by International Medical News Group